Form 4: Kalaris Therapeutics Director Receives Stock Option Grant

Director Michael Dybbs was granted 9,000 stock options in Kalaris Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Michael Dybbs received a grant of 9,000 stock options on June 3, 2026.
• The options have an exercise price of $4.72 per share.
• The options are scheduled to vest in full on the earlier of June 3, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the director.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership retention and alignment with corporate performance milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for small-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 3, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Kalaris Therapeutics, KLRS, Form 4, Stock Options, Director Compensation, Insider Transaction